

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM583139

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	SECURITY INTEREST		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
Genapsys, Inc.		06/23/2020	Corporation: DELAWARE
RECEIVING PARTY DATA			
Name:	Oxford Finance LLC		
Street Address:	133 North Fairfax Street		
City:	Alexandria		
State/Country:	VIRGINIA		
Postal Code:	22314		
Entity Type:	Limited Liability Company: DELAWARE		
PROPERTY NUMBERS Total: 1			
Property Type	Number	Word Mark	
Serial Number:	87891548	GENAPSYS	
CORRESPONDENCE DATA			
Fax Number:			
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	2023704750		
Email:	ipteam@cogencyglobal.com		
Correspondent Name:	Jennifer Countz		
Address Line 1:	1025 Vermont Ave NW, Suite 1130		
Address Line 2:	COGENCY GLOBAL INC.		
Address Line 4:	Washington, D.C. 20005		
ATTORNEY DOCKET NUMBER:	1235304		
NAME OF SUBMITTER:	David Hackett		
SIGNATURE:	/David Hackett/		
DATE SIGNED:	06/25/2020		
Total Attachments: 15			
source=Binder1#page3.tif			
source=Binder1#page4.tif			
source=Binder1#page5.tif			
source=Binder1#page6.tif			

OP \$40.00 87891548

source=Binder1#page7.tif
source=Binder1#page8.tif
source=Binder1#page9.tif
source=Binder1#page10.tif
source=Binder1#page11.tif
source=Binder1#page12.tif
source=Binder1#page13.tif
source=Binder1#page14.tif
source=Binder1#page15.tif
source=Binder1#page16.tif
source=Binder1#page17.tif

INTELLECTUAL PROPERTY SECURITY AGREEMENT

This Intellectual Property Security Agreement is entered into as of June 23, 2020 by and between OXFORD FINANCE LLC, as collateral agent for the Lenders (the "Lenders") described in the Loan Agreement (in such capacity, the "Collateral Agent") and GENAPSYS, INC. ("Grantor").

RECITALS

A. Lenders have agreed to make certain advances of money and to extend certain financial accommodation to Grantor (the "Loans") in the amounts and manner set forth in that certain Loan and Security Agreement by and between Collateral Agent, the Lenders and Grantor dated the Effective Date (as the same may be amended, modified or supplemented from time to time, including but not limited to pursuant to that certain First Amendment to Loan and Security Agreement dated as of even date herewith, the "Loan Agreement"; capitalized terms used herein are used as defined in the Loan Agreement). The Lenders are willing to make the Loans to Grantor, but only upon the condition, among others, that Grantor shall grant to Collateral Agent, for the benefit of the Lenders, a security interest in certain Copyrights, Trademarks, Patents, and mask works to secure the obligations of Grantor under the Loan Agreement.

B. Pursuant to the terms of the Loan Agreement, Grantor has granted to Collateral Agent, for the benefit of the Lenders, a security interest in all of Grantor's right, title and interest, whether presently existing or hereafter acquired, in, to and under all of the Collateral.

NOW, THEREFORE, for good and valuable consideration, receipt of which is hereby acknowledged, and intending to be legally bound, as collateral security for the prompt and complete payment when due of its obligations under the Loan Agreement, the parties hereto agree as follows:

AGREEMENT

To secure its obligations under the Loan Agreement, Grantor grants and pledges to Collateral Agent, for the benefit of the Lenders, a security interest in all of Grantor's right, title and interest in, to and under (i) its Intellectual Property Collateral (including without limitation those Copyrights, Patents and Trademarks listed on Exhibits A, B and C hereto), and (ii) all proceeds thereof (such as, by way of example but not by way of limitation, license royalties and proceeds of infringement suits), the right to sue for past, present and future infringements, and all rights corresponding thereto throughout the world and all re-issues, divisions continuations, renewals, extensions and continuations-in-part thereof.

This security interest is granted in conjunction with the security interest granted to Collateral Agent, for the benefit of the Lenders, under the Loan Agreement. The rights and remedies of Collateral Agent with respect to the security interest granted hereby are in addition to those set forth in the Loan Agreement and the other Loan Documents, and those which are now or hereafter available to Collateral Agent, for the benefit of the Lenders, as a matter of law or equity. Each right, power and remedy of Collateral Agent provided for herein or in the Loan Agreement or any of the Loan Documents, or now or hereafter existing at law or in equity shall be cumulative and concurrent and shall be in addition to every right, power or remedy provided

for herein and the exercise by Collateral Agent of any one or more of the rights, powers or remedies provided for in this Intellectual Property Security Agreement, the Loan Agreement or any of the other Loan Documents, or now or hereafter existing at law or in equity, shall not preclude the simultaneous or later exercise by any person, including Lender, of any or all other rights, powers or remedies.

[Balance of Page Intentionally Left Blank]

IN WITNESS WHEREOF, the parties have caused this Intellectual Property Security Agreement to be duly executed by its officers thereunto duly authorized as of the first date written above.


GRANTOR:

Address of Grantor:

GENAPSYS, INC.

GENAPSYS, INC.
200 Cardinal Way, Third Floor

Redwood City, CA 94063
Attn: Chief Executive Officer

By:  _____
Name: Hesaam Esfandyarpour
Title: CEO

COLLATERAL AGENT:

Address of Lender:

OXFORD FINANCE LLC

Oxford Finance LLC
133 North Fairfax Street
Alexandria, Virginia 22314

Attn: Legal Department

By: _____
Name: _____
Title: _____

IN WITNESS WHEREOF, the parties have caused this Intellectual Property Security Agreement to be duly executed by its officers thereunto duly authorized as of the first date written above.

GRANTOR:

Address of Grantor:

GENAPSYS, INC.

GENAPSYS, INC.
200 Cardinal Way, Third Floor

Redwood City, CA 94063
Attn: Chief Executive Officer

By: _____

Name: _____

Title: _____

Address of Lender:

Oxford Finance LLC
133 North Fairfax Street
Alexandria, Virginia 22314

COLLATERAL AGENT:

OXFORD FINANCE LLC

By: _____

Name: Colette H. Featherly

Title: Senior Vice President

Attn: Legal Department

EXHIBIT A

Copyrights

Description

Registration
Number

Registration Date

None

EXHIBIT B

Patents

<u>Country</u>	<u>Application Number</u>	<u>Filing Date</u>	<u>Patent Number</u>
United States of America	<u>61/389,484</u>	<u>10/04/10</u>	-
United States of America	<u>61/389,490</u>	<u>10/04/10</u>	-
United States of America	<u>61/443,167</u>	<u>02/15/11</u>	-
United States of America	<u>61/491,081</u>	<u>05/27/11</u>	-
United States of America	<u>61/565,651</u>	<u>12/01/11</u>	-
United States of America	<u>61/620,381</u>	<u>04/04/12</u>	-
United States of America	<u>13/632,513</u>	<u>10/01/12</u>	<u>8,969,002</u>
United States of America	<u>14/596,111</u>	<u>01/13/15</u>	<u>9,150,915</u>
United States of America	<u>14/835,070</u>	<u>08/25/15</u>	<u>9,533,305</u>
United States of America	<u>15/360,369</u>	<u>11/23/16</u>	<u>10,472,674</u>
United States of America	<u>16/115,344</u>	<u>08/28/18</u>	-
United States of America	<u>16/592,545</u>	<u>10/03/19</u>	-
United States of America	<u>15/931,845</u>	<u>05/14/20</u>	-
United States of America	<u>14/859,725</u>	<u>09/21/15</u>	<u>10,100,356</u>
United States of America	<u>13/397,581</u>	<u>02/15/12</u>	-

<u>Patent Cooperation Treaty</u>	<u>PCT/US2011/054769</u>	<u>10/04/11</u>	-
<u>European Patent Convention</u>	<u>11831452.5</u>	<u>10/04/11</u>	<u>2625526</u>
<u>European Patent Convention</u>	<u>12792216.9</u>	<u>05/29/12</u>	<u>2714935</u>
<u>European Patent Convention</u>	<u>12852490.7</u>	<u>12/03/12</u>	<u>2785868</u>
<u>Germany</u>	<u>12852490.7</u>	<u>12/03/12</u>	<u>2785868</u>
<u>Germany</u>	<u>11831452.5</u>	<u>10/04/11</u>	<u>2625526</u>
<u>Germany</u>	<u>12792216.9</u>	<u>05/29/12</u>	<u>2714935</u>
<u>France</u>	<u>12852490.7</u>	<u>12/03/12</u>	<u>2785868</u>
<u>France</u>	<u>11831452.5</u>	<u>10/04/11</u>	<u>2625526</u>
<u>France</u>	<u>12792216.9</u>	<u>05/29/12</u>	<u>2714935</u>
<u>United Kingdom</u>	<u>1308138.5</u>	<u>10/04/11</u>	<u>2499340</u>
<u>United Kingdom</u>	<u>12852490.7</u>	<u>12/03/12</u>	<u>2785868</u>
<u>United Kingdom</u>	<u>11831452.5</u>	<u>10/04/11</u>	<u>2625526</u>
<u>United Kingdom</u>	<u>12792216.9</u>	<u>05/29/12</u>	<u>2714935</u>
<u>Australia</u>	<u>2011312218</u>	<u>10/04/11</u>	<u>2011312218</u>
<u>Australia</u>	<u>2012262364</u>	<u>05/29/12</u>	<u>2012262364</u>
<u>Canada</u>	<u>2,837,486</u>	<u>05/29/12</u>	-
<u>China (People's Republic)</u>	<u>201180058407.4</u>	<u>10/04/11</u>	<u>ZL201180058407.4</u>
<u>China (People's Republic)</u>	<u>201280037449.4</u>	<u>05/29/12</u>	<u>ZL201280037449.4</u>
<u>China (People's Republic)</u>	<u>201280068919.3</u>	<u>12/03/12</u>	<u>ZL201280068919.3</u>
<u>China (People's Republic)</u>	<u>201610615115.0</u>	<u>12/03/12</u>	-
<u>Israel</u>	<u>225558</u>	<u>10/04/11</u>	<u>225558</u>
<u>Japan</u>	<u>2013-532882</u>	<u>10/04/11</u>	<u>6114694</u>

<u>Japan</u>	<u>2014-513646</u>	<u>05/29/12</u>	<u>5982472</u>
<u>Japan</u>	<u>2014-544986</u>	<u>12/03/12</u>	<u>6193252</u>
<u>Korea, Republic of</u>	<u>10-2013-7011609</u>	<u>10/04/11</u>	<u>10-1963462</u>
<u>Korea, Republic of</u>	<u>10-2013-7034832</u>	<u>05/29/12</u>	<u>10-1940833</u>
<u>Mexico</u>	<u>MX/a/2013/003860</u>	<u>10/04/11</u>	<u>344363</u>
<u>New Zealand</u>	<u>610129</u>	<u>10/04/11</u>	<u>610129</u>
<u>Singapore</u>	<u>201302552-3</u>	<u>10/04/11</u>	<u>189839</u>
<u>Singapore</u>	<u>11201402760V</u>	<u>12/03/12</u>	<u>11201402760V</u>
<u>United States of America</u>	<u>13/824,129</u>	<u>11/04/13</u>	<u>9,187,783</u>
<u>Hong Kong</u>	<u>14101380.0</u>	<u>10/04/11</u>	<u>HK1188614</u>
<u>Hong Kong</u>	<u>14109622.1</u>	<u>05/29/12</u>	<u>HK1196858</u>
<u>Hong Kong</u>	<u>15103103.1</u>	<u>12/03/12</u>	<u>HK1202591</u>
<u>United States of America</u>	<u>61/799,396</u>	<u>03/15/13</u>	-
<u>United States of America</u>	<u>15/726,217</u>	<u>10/05/17</u>	<u>10,570,449</u>
<u>United States of America</u>	<u>16/736,634</u>	<u>01/07/20</u>	-
<u>Patent Cooperation Treaty</u>	<u>PCT/US2014/027544</u>	<u>03/14/14</u>	-
<u>European Patent Convention</u>	<u>14767683.7</u>	<u>03/14/14</u>	<u>2971141</u>
<u>Germany</u>	<u>14767683.7</u>	<u>03/14/14</u>	<u>2971141</u>
<u>France</u>	<u>14767683.7</u>	<u>03/14/14</u>	<u>2971141</u>
<u>United Kingdom</u>	<u>14767683.7</u>	<u>03/14/14</u>	<u>2971141</u>
<u>Canada</u>	<u>2,896,879</u>	<u>03/14/14</u>	-
<u>China (People's Republic)</u>	<u>201480015628.7</u>	<u>03/14/14</u>	<u>ZL 201480015628.7</u>
<u>United States of America</u>	<u>14/653,230</u>	<u>06/17/15</u>	<u>9,809,852</u>

<u>United States of America</u>	<u>61/799,483</u>	<u>03/15/13</u>	-
<u>United States of America</u>	<u>61/799,944</u>	<u>03/15/13</u>	-
<u>United States of America</u>	<u>61/800,410</u>	<u>03/15/13</u>	-
<u>United States of America</u>	<u>61/800,443</u>	<u>03/15/13</u>	-
<u>United States of America</u>	<u>61/801,560</u>	<u>03/15/13</u>	-
<u>United States of America</u>	<u>61/801,929</u>	<u>03/15/13</u>	-
<u>United States of America</u>	<u>61/914,937</u>	<u>12/11/13</u>	-
<u>United States of America</u>	<u>16/137,408</u>	<u>09/20/18</u>	-
<u>United States of America</u>	<u>15/930,719</u>	<u>05/13/20</u>	-
<u>Patent Cooperation Treaty</u>	<u>PCT/US2014/069624</u>	<u>12/10/14</u>	-
<u>European Patent Convention</u>	<u>14869402.9</u>	<u>12/10/14</u>	-
<u>United States of America</u>	<u>15/028,899</u>	<u>04/12/16</u>	<u>10,125,393</u>
<u>United States of America</u>	<u>61/914,830</u>	<u>12/11/13</u>	-
<u>United States of America</u>	<u>61/915,276</u>	<u>12/12/13</u>	-
<u>United States of America</u>	<u>61/915,438</u>	<u>12/12/13</u>	-
<u>United States of America</u>	<u>62/047,583</u>	<u>09/08/14</u>	-
<u>United States of America</u>	<u>61/914,659</u>	<u>12/11/13</u>	-
<u>United States of America</u>	<u>61/914,826</u>	<u>12/11/13</u>	-

<u>United States of America</u>	<u>61/914,809</u>	<u>12/11/13</u>	-
<u>United States of America</u>	<u>61/914,902</u>	<u>12/11/13</u>	-
<u>United States of America</u>	<u>61/914,787</u>	<u>12/11/13</u>	-
<u>United States of America</u>	<u>61/940,343</u>	<u>02/14/14</u>	-
<u>United States of America</u>	<u>61/952,829</u>	<u>03/13/14</u>	-
<u>United States of America</u>	<u>14/656,028</u>	<u>03/12/15</u>	<u>9,630,177</u>
<u>United States of America</u>	<u>15/380,566</u>	<u>12/15/16</u>	<u>10,413,900</u>
<u>United States of America</u>	<u>16/534,412</u>	<u>08/07/19</u>	-
<u>Patent Cooperation Treaty</u>	<u>PCT/US2015/020130</u>	<u>03/12/15</u>	-
<u>European Patent Convention</u>	<u>15761225.0</u>	<u>03/12/15</u>	-
<u>China (People's Republic)</u>	<u>201580024734.6</u>	<u>03/12/15</u>	<u>ZL201580024734.6</u>
<u>United States of America</u>	<u>61/981,435</u>	<u>04/18/14</u>	-
<u>United States of America</u>	<u>62/025,626</u>	<u>07/17/14</u>	-
<u>United States of America</u>	<u>14/688,764</u>	<u>04/16/15</u>	<u>9,822,401</u>
<u>United States of America</u>	<u>15/726,193</u>	<u>10/05/17</u>	<u>10,533,218</u>
<u>United States of America</u>	<u>16/694,367</u>	<u>11/25/19</u>	-
<u>Patent Cooperation Treaty</u>	<u>PCT/US2015/026135</u>	<u>04/16/15</u>	-
<u>European Patent Convention</u>	<u>15779780.4</u>	<u>04/16/15</u>	<u>3132060</u>

<u>European Patent Convention</u>	<u>19162225.7</u>	<u>04/16/15</u>	-
<u>Germany</u>	<u>15779780.4</u>	<u>04/16/15</u>	<u>3132060</u>
<u>France</u>	<u>15779780.4</u>	<u>04/16/15</u>	<u>3132060</u>
<u>United Kingdom</u>	<u>15779780.4</u>	<u>04/16/15</u>	<u>3132060</u>
<u>United States of America</u>	<u>62/113,283</u>	<u>02/06/15</u>	-
<u>United States of America</u>	<u>15/662,692</u>	<u>07/28/17</u>	-
<u>Patent Cooperation Treaty</u>	<u>PCT/US2016/016813</u>	<u>02/05/16</u>	-
<u>European Patent Convention</u>	<u>16747351.1</u>	<u>02/05/16</u>	-
<u>China (People's Republic)</u>	<u>201680018871.3</u>	<u>02/05/16</u>	-
<u>United States of America</u>	<u>62/119,083</u>	<u>02/20/15</u>	-
<u>United States of America</u>	<u>62/140,399</u>	<u>03/30/15</u>	-
<u>United States of America</u>	<u>62/172,647</u>	<u>06/08/15</u>	-
<u>United States of America</u>	<u>62/196,224</u>	<u>07/23/15</u>	-
<u>United States of America</u>	<u>62/241,954</u>	<u>10/15/15</u>	-
<u>United States of America</u>	<u>15/707,880</u>	<u>09/18/17</u>	<u>10,683,389</u>
<u>United States of America</u>	<u>16/867,652</u>	<u>05/06/20</u>	-
<u>Patent Cooperation Treaty</u>	<u>PCT/US2016/023899</u>	<u>03/24/16</u>	-
<u>European Patent Convention</u>	<u>16773777.4</u>	<u>03/24/16</u>	-
<u>China (People's Republic)</u>	<u>201680031715.0</u>	<u>03/24/16</u>	-

<u>United States of America</u>	<u>62/216,124</u>	<u>09/09/15</u>	-
<u>United States of America</u>	<u>62/400,904</u>	<u>09/28/16</u>	-
<u>United States of America</u>	<u>62/364,489</u>	<u>07/20/16</u>	-
<u>United States of America</u>	<u>15/655,616</u>	<u>07/20/17</u>	<u>10,544,456</u>
<u>United States of America</u>	<u>16/712,601</u>	<u>12/12/19</u>	-
<u>Patent Cooperation Treaty</u>	<u>PCT/US2017/043159</u>	<u>07/20/17</u>	-
<u>European Patent Convention</u>	<u>17831906.7</u>	<u>07/20/17</u>	-
<u>China (People's Republic)</u>	<u>201780057996.1</u>	<u>07/20/17</u>	-
<u>United States of America</u>	<u>62/375,197</u>	<u>08/15/16</u>	-
<u>United States of America</u>	<u>62/418,101</u>	<u>11/04/16</u>	-
<u>United States of America</u>	<u>62/444,700</u>	<u>01/10/17</u>	-
<u>United States of America</u>	<u>62/561,358</u>	<u>09/21/17</u>	-
<u>United States of America</u>	<u>62/655,083</u>	<u>04/09/18</u>	-
<u>United States of America</u>	<u>16/141,215</u>	<u>09/25/18</u>	-
<u>Patent Cooperation Treaty</u>	<u>PCT/US2018/052072</u>	<u>09/20/18</u>	-
<u>European Patent Convention</u>	<u>18857574.0</u>	<u>09/20/18</u>	-
<u>Canada</u>	<u>3,076,378</u>	<u>09/20/18</u>	-
<u>China (People's Republic)</u>	<u>To be determined</u>	<u>09/21/18</u>	-

<u>Israel</u>	<u>273426</u>	<u>09/20/18</u>	-
<u>Japan</u>	<u>2020-516509</u>	<u>09/20/18</u>	-
<u>Mexico</u>	<u>MX/a/2020/003113</u>	<u>09/20/18</u>	-
<u>Singapore</u>	<u>11202002516W</u>	<u>09/20/18</u>	-
<u>United States of America</u>	<u>15/183,406</u>	<u>06/15/16</u>	-
<u>United States of America</u>	<u>13/481,858</u>	<u>05/27/12</u>	<u>9,399,217</u>
<u>United States of America</u>	<u>13/838,816</u>	<u>03/15/13</u>	<u>9,274,077</u>
<u>United States of America</u>	<u>15/896,572</u>	<u>02/14/18</u>	-
<u>United States of America</u>	<u>16/007,829</u>	<u>06/13/18</u>	<u>10,260,095</u>
<u>United States of America</u>	<u>16/007,969</u>	<u>06/13/18</u>	<u>10,266,892</u>
<u>United States of America</u>	<u>16/039,016</u>	<u>07/18/18</u>	-
<u>United States of America</u>	<u>16/283,531</u>	<u>02/22/19</u>	<u>10,612,091</u>
<u>United States of America</u>	<u>16/283,544</u>	<u>02/22/19</u>	<u>10,494,672</u>
<u>United States of America</u>	<u>16/598,591</u>	<u>10/10/19</u>	-
<u>Patent Cooperation Treaty</u>	<u>PCT/US2012/039880</u>	<u>05/29/12</u>	-
<u>United States of America</u>	<u>14/119,859</u>	<u>04/15/14</u>	<u>9,926,596</u>
<u>United States of America</u>	<u>16/105,480</u>	<u>08/20/18</u>	-
<u>Patent Cooperation Treaty</u>	<u>PCT/US2012/067645</u>	<u>12/03/12</u>	-
<u>United States of America</u>	<u>14/361,902</u>	<u>05/30/14</u>	<u>10,093,975</u>

<u>United States of America</u>	<u>62/978.735</u>	<u>02/19/20</u>	-
<u>United States of America</u>	<u>62/978.744</u>	<u>02/19/20</u>	-
<u>United States of America</u>	<u>62/976.982</u>	<u>02/14/20</u>	-
<u>United States of America</u>	<u>62/987.818</u>	<u>03/10/20</u>	-

EXHIBIT C

Trademarks

<u>Description</u>	<u>Serial/Registration No.</u>	<u>File Date</u>
GENAPSYS	87891548	4/24/18